{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+%2B+Prednisolone%2FPrednisone", "query": { "intervention": "Abiraterone + Prednisolone/Prednisone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+%2B+Prednisolone%2FPrednisone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T18:29:57.115Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01381874", "title": "A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic ER+ Her2- Breast Cancer", "Postmenopausal" ], "interventions": [ { "name": "Exemestane", "type": "DRUG" }, { "name": "Abiraterone acetate + Prednisone/ Prednisolone + Exemestane", "type": "DRUG" }, { "name": "Abiraterone acetate + Prednisone or Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 297, "start_date": "2011-08-24", "completion_date": "2018-08-08", "has_results": true, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 24, "location_summary": "Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381874" }, { "nct_id": "NCT06952803", "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone + Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 700, "start_date": "2025-08-06", "completion_date": "2036-04-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952803" }, { "nct_id": "NCT05288166", "title": "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Neoplasm Metastasis", "Urogenital Neoplasms", "Physiological Effects of Drugs", "Antineoplastic Agents", "Antineoplastic Agents, Hormonal", "Androgens", "Hormones", "Hormones, Hormone Substitutes, and Hormone Antagonists", "Abiraterone Acetate", "Steroid Synthesis Inhibitors", "Cytochrome P-450", "Enzyme Inhibitors", "Prednisone", "Prednisolone", "Cyclin-Dependent Kinase 4", "Cyclin-Dependent Kinase 6" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" }, { "name": "Placebo for Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 925, "start_date": "2022-04-14", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 63, "location_summary": "Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05288166" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 26, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT03732820", "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 895, "start_date": "2018-10-31", "completion_date": "2027-02-05", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732820" }, { "nct_id": "NCT01517802", "title": "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 32, "start_date": "2012-03-28", "completion_date": "2021-04-22", "has_results": true, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 10, "location_summary": "Aurora, Colorado • Marrero, Louisiana • Boston, Massachusetts + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Marrero", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "East Setauket", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517802" }, { "nct_id": "NCT04666129", "title": "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Castration-Sensitive Prostate Cancer", "Non-Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2021-02-18", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 16, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666129" }, { "nct_id": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Breast Cancer", "Non-small Cell Lung Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2018-07-23", "completion_date": "2025-07-06", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568656" }, { "nct_id": "NCT03834519", "title": "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 793, "start_date": "2019-05-02", "completion_date": "2024-01-27", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 29, "location_summary": "Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Quincy", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834519" }, { "nct_id": "NCT00485303", "title": "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2007-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-04T18:29:57.115Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485303" } ] }